Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-AIC
NCT06888505Phase 2Completed
- Sponsor
- Hawler Medical University
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in anthracycline-induced cardiotoxicity (2 arms), sponsored by Hawler Medical University. Primary endpoint: Left Ventricular Ejection Fraction at 4 months. Started Sep 2024; status: completed.
02
Drugs
dapagliflozin
03
Conditions
anthracycline-induced cardiotoxicity
Beyond the preview
Go deeper on NCT06888505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06888505.